transplantation. The addition of FLU enhanced engraftment three-fold. The incidence of grades II-IV acute and chronic graft-versus-host disease (GVHD) was 20% and 10%, respectively. Severe toxicity was highest in patients >10 years of age, or with a history of opportunistic infections or transfusions prior to HCT. Mortality was lowest in patients without a prior history of opportunistic infection or transfusions, and who received conditioning with TBI 300 cGy, CY, FLU and ATG. These patients had a probability of survival of 94% at 5 years. Alternative donor HCT is now associated with excellent survival for patients without prior opportunistic infections or transfusions and should be considered for all FA patients after the onset of marrow failure. Studies were registered at http://www.clinicaltrials.gov as NCT00005898, NCT00167206 and NCT00352976.
Introduction
Fanconi anemia (FA) is a rare, genetically and phenotypically heterogeneous inherited disorder characterized by congenital malformations, progressive bone marrow (BM) failure, and marked predisposition to malignancy. 1 Hematological abnormalities occur in at least 90% of FA patients at a median onset of 7 years 2,3 and allogeneic hematopoietic cell transplantation (HCT) is the only proven potential curative therapy. 4 Most FA patients do not have a human leukocyte antigen (HLA)-identical unaffected sibling donor and therefore require an alternative (HLA-matched related or unrelated) donor. Early experiences with alternative donor HCT for the treatment of the hematological complications of FA were discouraging, with long term survival rates of approximately 30%. 5, 6 Poor outcomes were often the result of graft failure in 25-30% patients, graftversus-host disease (GVHD) in 50-70% patients, excessive regimen-related toxicities, and opportunistic infections. 5, 6 To improve outcomes, we made sequential changes to the HCT conditioning regimen in a series of 4 prospective clinical trials. The aim of this analysis was to identify patient, treatment and graft related factors associated with favorable outcomes.
Patient and Methods

Study Design
This is an analysis of all patients with FA undergoing alternative donor HCT at the For personal use only. on April 7, 2017 . by guest www.bloodjournal.org From
Patients
Eligible patients had FA with severe marrow failure (defined as having either hemoglobin <8 g/dL, platelet count <20 x 10 9 /L, and/or absolute neutrophil count <5 x 10 8 /L), advanced myelodysplastic syndrome (MDS with ≥ 5% blasts), or acute leukemia 7 .
Patients were excluded from transplant if organ function was inadequate (i.e., left ventricular ejection fraction <45%, any liver function test >5 x normal, oxygen saturation <92% in room air), for poor performance status (Karnofsky <70% or Lansky <50%), active uncontrolled infection, or a history of squamous cell carcinoma within 2 years.
Transplant Procedure
All patients received a conditioning regimen containing a single fraction total body Table 1 .
Marrow from a 7/8 allele level HLA matched related or 7-8/8 allele level HLA matched unrelated donor was ex vivo T-cell depleted with an add back of T-cells to achieve a fixed graft T cell dose of 1 x 10 5 CD3/kg recipient. Unmanipulated 4-6/6 HLA matched unrelated umbilical cord blood (UCB) was used based on standard matching criteria. 9 For personal use only. on April 7, 2017 . by guest www.bloodjournal.org From In all groups, TBI was administered in a single fraction delivered with AP and PA fields at extended distance (dose rate was 26 cGy/minute) on day -6 before HCT. The TBI dose was prescribed at the midplane of the patient at the midpelvis. Lung compensators were designed to maintain prescribed dose (+/-5%) to the lungs. For thymic shielding, a contrast enhanced treatment planning CT scan was performed to locate the thymus.
5HVL cerrobend blocks were fabricated and placed to block the thymus with a 1 cm margin from both the anterior and posterior total body irradiation fields. CMV reactivation was monitored weekly until at least day 100 following transplant and pre-emptively treated with ganciclovir or foscarnet.
Endpoint Definitions
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Statistical Analysis
For personal use only. on April 7, 2017 . by guest www.bloodjournal.org From Kaplan-Meier curves were used to estimate the probability of survival. 12 The log-rank test was used to compare outcomes between groups. Cox regression was used to examine the independent effect of factors on survival. 13 time-dependent acute GVHD, and prior androgen therapy (yes vs. no).
All factors were tested for violations of the proportional hazards assumption using Martingale residuals. Neutrophil recovery, platelet recovery, acute and chronic GVHD, regimen-related toxicities, opportunistic infections, and mortality were estimated with cumulative incidence treating non-event deaths as a competing risk. 14 Fine and Gray regression was used to examine the independent effect of factors for these endpoints. 15 The adjusted overall survival and engraftment curves of different types of conditioning in 
Results
Patient and Donor Characteristics
One hundred and thirty patients with FA, median age 9.0 years (range 1-48) with 19 (15%) >18 years), underwent alternative donor HCT ( Table 2 ). The population reflects the expected distribution of FA gene mutations (68% FANCA, 20% FANCC, 1%
FANCD1, 1% FANCE, 2% FANCF, and 8% FANCG of the 100 patients with known mutations). DEB mosaicism (i.e. presence of ≥ 10% DEB resistant cells) was present in 36% patients. Prior to HCT, patients were treated for opportunistic infections 11 (11%), or cytopenias with blood products (74%), hematopoietic growth factors (48%), or androgens (38%). Median follow-up was 7.7 years (range 1.8 -18.8).
Survival
For the entire cohort, the probability of survival at 1 year was 63% [95% confidence interval (CI), 54-71%], at 5 years 58% (95% CI, 49-59%), and at 10 years 57% (95% CI, 47-65%). In regression analysis, recipients of FLU-containing regimens had a lower risk of mortality at 5 years (Table 3) especially those who received FLU and TBI 300cGy
For personal use only. on April 7, 2017 . by guest www.bloodjournal.org Causes of death were graft failure (n=5), GVHD (n=10), regimen related toxicity (n=13), opportunistic infection (n=17), relapse (n=4), post transplant lymphoproliferative disease (n=2), and new malignancy (n=2).
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Hematopoietic Recovery
The incidence of neutrophil recovery was 90% (95% CI, 84-95%) at a median of 12 days Platelet recovery data were not collected for patients transplanted prior to 2000, restricting this analysis to 105 patients. For these patients, all of whom received a FLUcontaining regimen, the incidence of platelet recovery by 6 months was 77% (95% CI, 65-89%) at a median of 40.5 days (range . In regression analysis, factors associated with platelet recovery were use of androgens prior to transplant and hematopoietic stem cell source. Patients who received androgens prior to transplant (RR 0.5, 95% CI, 0.3-0.9, p = 0.02) or transplanted with UCB (RR 0.5, 95% CI, 0.3-0.8, p = 0.01) were less likely to achieve platelet recovery by 6 months. Importantly, no other factors including DEB mosaicism, TBI dose, use of thymic shielding, or cell dose adversely affect neutrophil or platelet recovery engraftment.
Graft-Versus-Host Disease
The incidence of grade II-IV and grade III-IV acute GVHD was 20% (95% CI, 13-27%) and 9% (95% CI, 4-14%), respectively. In regression analysis, the only factor associated with acute GVHD was hematopoietic stem cell source. Recipients of unrelated donor 7/8 HLA-matched T-cell depleted BM (RR 2.8, 95% CI, 1.1-7.4, p=0.03) or 4-6/6 HLA-matched UCB (RR 2.9; 95% CI, 1.2-7.0, p=0.02) were more likely to have grade II-IV acute GVHD than recipients of HLA-matched T-cell depleted BM. Similarly, recipients of unrelated donor HLA-mismatched T-cell depleted BM (RR 4.5, 95% CI, 1.1-19.1, p=0.04) or UCB (RR 5.5, 95% C, 1.4-22.1; p=0.02) were more likely to have severe (grade III-IV) acute GVHD than recipients of HLA-matched T-cell depleted BM.
The overall incidence of chronic GVHD was 10% (95% CI, 5-15%) at 2 years. In regression analysis, the only factor associated with chronic GVHD was the use of androgens prior to transplant (RR 3.4, 95% CI, 1.1-10.6, p=0.03). No other factor was associated with developing chronic GVHD although there was a trend toward higher chronic GVHD in patients with prior acute GVHD (RR 3.8, 95% CI, 0.8-17.9, p = 0.09).
Regimen-Related Toxicity
Detailed toxicity data were available for patients transplanted after 1999 (Table 5) . For these patients, the overall incidence of any non-hematological severe (grade 4 or 5) toxicity was 43% (95% CI, 34-52%). In regression analysis, factors associated with the development of severe regimen-related toxicities were older age (≥10 years [odds ratio No other factor including preparative therapy or graft source showed significant association with severe regimen-related toxicities.
For
Opportunistic Infections
One hundred and seventy six severe opportunistic infection events were reported in the 105 patients transplanted after 1999. Forty-five patients did not develop any opportunistic infections. Among severe opportunistic infections, 58% were bacterial, 31% were viral and 11% were fungal. Among the disseminated fungal infections, yeast infections by Candida (n=12) occurred more often than mold infections caused by Aspergillus (n=7).
The frequency of all opportunistic infections per patient was higher in patients with a 
Relapse and New Malignancies
Two of 10 patients with advanced MDS or acute leukemia relapsed at 32 days and 175 days after transplant for an incidence of 20% (95% CI, 1-45%). Twelve patients had EBV reactivation with 8 developing post transplant lymphoproliferative disease (PTLD), of whom 7 received unrelated donor BM and one UCB as grafts. Four patients died from PTLD or complications of therapy. Three patients developed non lympho-hematological
after transplant for an overall incidence of 3% (95% CI, 0-6%). All three had squamous cell carcinoma (mouth in two, lung in one) at 1, 12.4 and 14 years after transplant. None of these patients had a history of acute or chronic GVHD.
Discussion
This is the largest single center experience of alternative donor HCT for the treatment of the hematological manifestations of FA. Establishing the optimal approach to achieve engraftment without excessive toxicity has been particularly challenging for FA patients due to their inherent DNA repair defect and intolerance to conventional doses of chemotherapy and radiation. 
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